RecruitingPhase 1Phase 2NCT06885281
A Study of ZL-1310 in Participants With Selected Solid Tumors
A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors
Sponsor
Zai Lab (Shanghai) Co., Ltd.
Enrollment
166 participants
Start Date
May 12, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called ZL-1310 for people with solid tumors. The study is currently recruiting participants at 21 locations. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGZL-1310
drug ZL-1310
Locations(23)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06885281
Related Trials
Personalized Neoantigen Peptide Vaccines for Solid Tumors
NCT070022031 location
A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors
NCT072312111 location
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
NCT045704235 locations
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
NCT0393437223 locations
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873781 locations